Skip to main content

Table 1 Quality assessment of all included studies

From: Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis

Study

Selection

Comparability

Exposure

Randomization

Masking

Accountability of all patients

Quality (score)

Randomized controlled trial

 2012

Kim [26]

   

4

 2016

Urata [10]

   

5

 2017

Yang [11]

   

5

Retrospective study

 2010

Kim [19]

   

7

 2010

Hotta [20]

   

9

 2010

Hong [21]

   

7

 2011

Wu [22]

   

9

 2011

Shin [12]

   

7

 2011

Togashi [23]

   

8

 2011

Fan [14]

   

8

 2011

Jung [24]

   

6

 2012

Wu [25]

   

8

 2012

Suzumura [27]

   

8

 2013

Yoshida [28]

   

8

 2013

Shao [29]

   

9

 2013

Lee [30]

   

8

 2013

Yu [31]

   

8

 2014

Lim [32]

   

9

 2014

Sato [13]

   

8

 2014

Lin [33]

   

7

 2014

Ren [34]

   

8

 2014

Li [35]

   

8

 2014

Takeda [36]

   

6

 2015

Otsuka [37]

   

9

 2015

Song [38]

   

7

 2015

Koo [39]

   

7

 2016

Ruan [40]

   

8

 2016

Hirano [41]

   

8

 2016

Suh [42]

   

7

 2016

Kashima [43]

   

8

 2017

Kuan [15]

   

8